If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

Share Price is delayed by 15 minutes
Get Live Data
33.80    0.00 (0.00%)
Bid:
32.80
Ask:
34.80
Spread: 2.00 (6.098%)
Market Cap: £70.16m
MIG1 Live PriceLast checked at - London Stock Exchange

Intraday Maven Income 1 Share Chart

Result of AGM

7 Jul 2022 14:34

RNS Number : 7274R
Maven Income & Growth VCT PLC
07 July 2022
 

 

Maven Income and Growth VCT PLC

 

Result of Annual General Meeting

 

At the Annual General Meeting of the Company held at Fifth Floor, 1-2 Royal Exchange Buildings, London EC3V 3LF, at 12.00 noon on Thursday 7 July 2022, all of the Resolutions put to the Meeting were passed.

 

At the record date for the Annual General Meeting, being 5 July 2022, the total number of voting rights in the Company stood at 134,323,293 and the total shares in issue were 134,323,293. The Company advises that, for the Annual General Meeting, valid proxy appointments were made in respect of 7,414,274 shares and that the number of proxy votes lodged for each Resolution were as follows:

 

 

Resolutions

For

Discretion

Against

Withheld

Total

1

To receive the Directors' Report and audited Financial Statements

7,034,433

358,155

0

21,686

7,414,274

2

To approve the Directors' Remuneration Report

6,315,078

377,672

540,152

181,372

7,414,274

3

To approve the payment of a final dividend

 

7,061,764

330,824

0

21,686

7,414,274

4

To re-elect John Pocock as a Director

 

6,734,665

346,836

200,079

132,694

7,414,274

5

To re-elect Alison Fielding as a Director

 

6,876,567

346,836

88,507

102,364

7,414,274

6

To re-elect Andrew Harrington as a Director

 

6,927,859

350,836

33,215

102,364

7,414,274

7

To re-elect Arthur MacMillan as a Director

 

6,775,727

346,836

147,698

144,013

7,414,274

8

To re-appoint Deloitte LLP as Auditor

 

6,409,239

354,002

601,256

49,777

7,414,274

9

To authorise the Directors to fix the remuneration of the Auditor

6,959,970

355,555

49,934

48,815

7,414,274

10

To renew the Company's authority to allot shares

6,625,871

321,417

448,167

18,819

7,414,274

11

To authorise the Directors to disapply pre-emption rights

6,434,993

321,417

599,828

58,036

7,414,274

12

To renew the Company's authority to purchase its own shares

6,611,079

321,417

438,935

42,843

7,414,274

13

To amend the minimum notice period for a general meeting

6,658,742

390,644

317,697

47,191

7,414,274

A vote withheld is not a vote in law and any such votes have not been included in the votes for or against the respective Resolutions. The voting figures will be available to view at: www.mavencp.com/migvct.

 

Passing of Resolutions under Special Business

Copies of Resolutions passed under Special Business have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism

 

Issued on behalf of the Board

Maven Capital Partners UK LLP

Secretary

7 July 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSSFFDWEESEDW
Date   Source Headline
1st Jul 20269:23 amRNSAdmission to Trading
26th Jun 20269:30 amRNSIssue of Equity
23rd Jun 20264:06 pmRNSAudited NAV - Dividend Investment Scheme
2nd Jun 20264:19 pmRNSAnnual Financial Report
1st May 20263:20 pmRNSTransaction in Own Shares
30th Apr 20265:09 pmRNSTransaction in Own Shares
30th Apr 202610:51 amRNSAdmission of Further Securities to Trading
29th Apr 202612:23 pmRNSIssue of Equity
27th Apr 20263:29 pmRNSUnaudited Net Asset Value and Dividend Declaration
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:17 amRNSAdmission of Further Securities to Trading
14th Apr 202611:06 amRNSIssue of Equity
8th Apr 20269:27 amRNSAdmission of Further Securities to Trading
25th Mar 202610:49 amRNSAdmission of Further Securities to Trading
24th Mar 202612:08 pmRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
29th Jan 20264:54 pmRNSTransaction in Own Shares
21st Jan 202611:01 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:39 amRNSIssue of Equity
15th Jan 202610:27 amRNSDirector/PDMR Shareholding
15th Jan 202610:26 amRNSDirector/PDMR Shareholding
15th Jan 202610:26 amRNSDirector/PDMR Shareholding
15th Jan 20269:50 amRNSIssue of Equity
14th Jan 20262:33 pmRNSUnaudited NAV - Dividend Investment Scheme
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20253:39 pmRNSResult of General Meeting
29th Oct 20257:00 amRNSHalf-year Report
16th Oct 20254:43 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:06 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:12 pmRNSStatement re Dividend Investment Scheme
23rd Jul 20254:33 pmRNSTransaction in Own Shares
18th Jul 202510:08 amRNSIssue of Equity - Dividend Investment Scheme
16th Jul 20257:08 amRNSStatement re Offer for Subscription
11th Jul 20253:56 pmRNSStatement re Dividend Investment Scheme
11th Jul 20252:58 pmRNSStatement re Unaudited NAV and Interim Dividend
10th Jul 20252:32 pmRNSResult of AGM
28th May 20254:18 pmRNSAnnual Financial Report
7th May 20254:35 pmRNSTransaction in Own Shares
6th May 202511:51 amRNSIssue of Equity
25th Apr 20254:19 pmRNSUnaudited NAV and Proposed Final Dividend
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:15 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:02 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
24th Mar 20253:23 pmRNSUnaudited Net Asset Value

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.